CN115335076B - 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 - Google Patents

编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Info

Publication number
CN115335076B
CN115335076B CN202180019813.3A CN202180019813A CN115335076B CN 115335076 B CN115335076 B CN 115335076B CN 202180019813 A CN202180019813 A CN 202180019813A CN 115335076 B CN115335076 B CN 115335076B
Authority
CN
China
Prior art keywords
leu
seq
pro
arg
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180019813.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115335076A (zh
Inventor
H·C·J·艾尔特
C·S·马高恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viral Therapy Co ltd
Wistar Institute of Anatomy and Biology
Original Assignee
Viral Therapy Co ltd
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viral Therapy Co ltd, Wistar Institute of Anatomy and Biology filed Critical Viral Therapy Co ltd
Priority to CN202511456350.3A priority Critical patent/CN121221754A/zh
Publication of CN115335076A publication Critical patent/CN115335076A/zh
Application granted granted Critical
Publication of CN115335076B publication Critical patent/CN115335076B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180019813.3A 2020-01-09 2021-01-08 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法 Active CN115335076B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202511456350.3A CN121221754A (zh) 2020-01-09 2021-01-08 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062958809P 2020-01-09 2020-01-09
US202062958827P 2020-01-09 2020-01-09
US62/958,809 2020-01-09
US62/958,827 2020-01-09
US202062967242P 2020-01-29 2020-01-29
US202062967104P 2020-01-29 2020-01-29
US62/967,242 2020-01-29
US62/967,104 2020-01-29
US202063064506P 2020-08-12 2020-08-12
US202063064571P 2020-08-12 2020-08-12
US63/064,506 2020-08-12
US63/064,571 2020-08-12
US202063112202P 2020-11-11 2020-11-11
US202063112219P 2020-11-11 2020-11-11
US63/112,219 2020-11-11
US63/112,202 2020-11-11
PCT/US2021/012630 WO2021142212A1 (en) 2020-01-09 2021-01-08 Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511456350.3A Division CN121221754A (zh) 2020-01-09 2021-01-08 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Publications (2)

Publication Number Publication Date
CN115335076A CN115335076A (zh) 2022-11-11
CN115335076B true CN115335076B (zh) 2025-10-28

Family

ID=74505354

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180019813.3A Active CN115335076B (zh) 2020-01-09 2021-01-08 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法
CN202511456350.3A Pending CN121221754A (zh) 2020-01-09 2021-01-08 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202511456350.3A Pending CN121221754A (zh) 2020-01-09 2021-01-08 编码与疱疹病毒糖蛋白d融合的乙型肝炎病毒抗原的腺病毒载体及其使用方法

Country Status (13)

Country Link
US (5) US12605444B2 (https=)
EP (1) EP4087605A1 (https=)
JP (2) JP7696909B2 (https=)
KR (1) KR20220163354A (https=)
CN (2) CN115335076B (https=)
AU (1) AU2021205936A1 (https=)
BR (1) BR112022013620A2 (https=)
CA (1) CA3166989A1 (https=)
IL (1) IL294387A (https=)
MX (1) MX2022008572A (https=)
PH (1) PH12022551648A1 (https=)
WO (1) WO2021142212A1 (https=)
ZA (1) ZA202310905B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294387A (en) * 2020-01-09 2022-08-01 Virion Therapeutics Llc Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074913A (zh) * 2014-06-23 2017-08-18 巴斯德研究院 包含非结构蛋白的片段的登革热病毒嵌合多表位及其在抗登革热病毒感染的免疫原性组合物中的用途
CN109414496A (zh) * 2016-04-06 2019-03-01 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054262A1 (en) 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
EA028659B1 (ru) * 2011-02-12 2017-12-29 Глоубиммьюн, Инк. Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
GB201223386D0 (en) * 2012-12-24 2013-02-06 Immune Targeting Systems Its Ltd Vaccine
CN105367662B (zh) * 2014-08-29 2021-03-12 汤正好 一种hbv相关的融合蛋白、其制备方法及其应用
SG11201900808SA (en) 2016-08-01 2019-02-27 Wistar Inst Compositions and methods of replication deficient adenoviral vectors for vaccine applications
CN119770638A (zh) * 2019-09-30 2025-04-08 吉利德科学公司 Hbv疫苗和治疗hbv的方法
IL294387A (en) * 2020-01-09 2022-08-01 Virion Therapeutics Llc Adenovirus vectors encoding hepatitis b virus antigens fused to herpesvirus glycoprotein d and methods of using them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074913A (zh) * 2014-06-23 2017-08-18 巴斯德研究院 包含非结构蛋白的片段的登革热病毒嵌合多表位及其在抗登革热病毒感染的免疫原性组合物中的用途
CN109414496A (zh) * 2016-04-06 2019-03-01 华盛顿大学 用于乙型肝炎病毒（hbv）的使用hbv核心抗原的治疗性疫苗

Also Published As

Publication number Publication date
KR20220163354A (ko) 2022-12-09
JP2025124904A (ja) 2025-08-26
US12605444B2 (en) 2026-04-21
CN121221754A (zh) 2025-12-30
JP7696909B2 (ja) 2025-06-23
IL294387A (en) 2022-08-01
JP2023510544A (ja) 2023-03-14
CA3166989A1 (en) 2021-07-15
US20220175913A1 (en) 2022-06-09
US11291716B2 (en) 2022-04-05
BR112022013620A2 (pt) 2022-09-13
ZA202310905B (en) 2025-06-25
US11850282B2 (en) 2023-12-26
US20240091347A1 (en) 2024-03-21
US20250228934A1 (en) 2025-07-17
EP4087605A1 (en) 2022-11-16
US20230063089A1 (en) 2023-03-02
CN115335076A (zh) 2022-11-11
US12290561B2 (en) 2025-05-06
WO2021142212A1 (en) 2021-07-15
PH12022551648A1 (en) 2024-02-12
MX2022008572A (es) 2022-09-23
AU2021205936A1 (en) 2022-07-21
US20210393770A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
US20230330215A1 (en) Sars-cov-2 vaccines
JP2022166122A (ja) 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
CN112368386A (zh) 共有抗原
Kosinska et al. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model
CN114340661A (zh) Hiv抗原和mhc复合物
Moffat et al. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells
CN115942942A (zh) 感染性疾病抗原和疫苗
CA3184791A1 (en) Cancer treatment strategies using arenavirus vectors
Ragonnaud et al. Therapeutic vaccine against primate papillomavirus infections of the cervix
US20180193446A1 (en) Dengue vaccines
JP2025124904A (ja) ヘルペスウイルス糖タンパク質ｄと融合したｂ型肝炎ウイルス抗原をコードするアデノウイルスベクター及びその使用方法
Ma et al. Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2. 1/Kb transgenic mice
CA3079776A1 (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
Dhalech et al. Coxsackievirus B3 elicits a sex-specific CD8+ T cell response which protects female mice
HK40082959A (en) Adenoviral vectors encoding hepatitis b viral antigens fused to herpes virus glycoprotein d and methods of using the same
EP4429699A2 (en) Sars-cov-2 vaccines
Tan et al. Construction and efficacy testing of DNA vaccines containing HLA-A* 02: 01-restricted SARS-CoV-2 T-cell epitopes predicted by immunoinformatics: DNA vaccines containing HLA-A* 02: 01-restricted SARS-CoV-2 T-cell epitopes
Lasaro et al. Vaccine-induced T cells provide partial protection against high-dose rectal SIVmac239 challenge of rhesus macaques
Li et al. Protection against SHIV‐KB9 Infection by Combining rDNA and rFPV Vaccines Based on HIV Multiepitope and p24 Protein in Chinese Rhesus Macaques
Escarra-Senmarti et al. A conserved region T-cell vaccine for Sarbecoviruses
Hirose et al. Keita Kawashiro, Rigel Suzuki 2, 3, 10, Takuto Nogimori 4, 10, Shuhei Tsujino 2, Naoya Iwahara
JP2025500258A (ja) 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40082959

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant